Sa1295 Development of Process and Outcome Quality Indicators for Inflammatory Bowel Disease (IBD)

2012 ◽  
Vol 142 (5) ◽  
pp. S-266
Author(s):  
Gil Melmed ◽  
Corey A. Siegel ◽  
Brennan M. Spiegel ◽  
John I. Allen ◽  
Robert R. Cima ◽  
...  
2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S112-S112
Author(s):  
P Bossuyt ◽  
D Baert ◽  
F Baert ◽  
E Hoefkens ◽  
I Huys ◽  
...  

Abstract Background Quality of care in inflammatory bowel disease (IBD) depends on multiple factors and is assessed through structure, process and outcome indicators. Structure and process indicators are more static and can easily be measured by an audit. Patient-oriented outcome indicators that impact on the quality of life are more difficult to assess. The aim of the project was to build a platform that automatically captures key outcome quality indicators and provide benchmarking output to improve quality of care in IBD centres. Methods Literature was reviewed for relevant quality indicators in IBD. After two non-anonymized Delphi like review and consensus meetings, twelve quality indicators were selected for implementation. The definitions of the outcomes were aligned in consensus with the available International Consortium for Health Outcomes Measurement (ICHOM). A web-based interface was built in three large volume IBD centres in Belgium to collect data on multiple ways: (i) Patients complete patient-reported outcome questionnaires and disease specific questions when attending the outpatient clinic and/or day clinic; (ii) The software automatically extracts data from the electronic medical files including biochemical and endoscopic reports; (iii) The medical baseline characteristics and outcome indicators for each patient are completed by the healthcare professional at inclusion and after this on a yearly basis. Results In total 265 patients were included in the participating IBD centres. Three indicators could be directly extracted from the patient-reported outcome questionnaires (clinical remission, fatigue, work productivity). Two items could be retrieved by use of the bot that automatically extracts biochemical and endoscopic reports from the medical files (anaemia, deep remission). The other items were collected throughout yearly confirmation by a health care professional (colorectal cancer, steroid use [systemic/topical], severe infections, hospital admission, IBD surgery [perianal/abdominal]). All items are benchmarked in an anonymous way on a benchmarking dashboard. Each centre can only see his own position in the benchmarking diagram. Additionally, the case mix per centre (type IBD, severity, demographic data) was added to the benchmarking output to provide a balanced evaluation of the outcome indicators. Conclusion This is the first partially automated benchmarking initiative for quality of care in IBD. The data collection is feasible and provides an objective assessment and comparison of the IBD related quality of care in different centres. Further prospective evaluation needs to confirm that implementation of benchmarking improves the performance and quality of IBD management.


2020 ◽  
Vol 32 (4) ◽  
pp. 523-525
Author(s):  
Pieter Sinonquel ◽  
Peter Bossuyt ◽  
Séverine Vermeire ◽  
Raf Bisschops

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S492-S493
Author(s):  
C Xu ◽  
V Byman ◽  
J Hossain ◽  
A Storlåhls ◽  
C Hedin

Abstract Background The development and clinical application of quality indicators (QI) for IBD are objectives of The Swedish inflammatory bowel disease registry (SWIBREG)(1). These include objective and subjective parameters aiming to standardise IBD care in Sweden(2).We aimed to evaluate QI target attainment at Karolinska University Hospital, and to identify specific patient or disease parameters associated with failure to reach QI targets. Methods QI targets as defined by SWIBREG were analysed in patients with Crohn′s disease undergoing treatment with biologics. A retrospective register-based study included 292 patients who received biological treatment between 2018-08-01 and 2020-01-31. Pediatric Crohn’s patients and patients with a treatment duration <6 months were excluded. Results Faecal Calprotectin (FC) and Haemoglobin (Hb) values were registered for 80% and 86%, respectively. Anaemia prevalence was 30%. Significantly lower monitoring frequencies were observed in patients undergoing treatment with Adalimumab and patients with biological treatment duration >1 year. FC was <250 μg/g in 77% of patients. The QI target for the frequency of Short Health Scale (SHS) registration was met whereas that of Physician Global Assessment (PGA) was not. The QI target for the most recent value of both SHS and PGA were met. Only 70% of smokers, 72% of patients with biological treatment duration >1 year and 52% of adalimumab patients had a registered SHS evaluation. Conclusion Adalimumab treatment, treatment duration and smoking are associated with decreased frequency of registration of QIs. Efforts are needed to ensure quality of care for these groups. A lower rate of PGA monitoring may reflect a lack of capacity for physician assessments and could be complemented with “professional global assessments” by specialist IBD nurses. References 1. Ludvigsson JF, Andersson M, Bengtsson J, Eberhardson M, Fagerberg UL, Grip O, et al. Swedish Inflammatory Bowel Disease Register (SWIBREG) - a nationwide quality register. Scand J Gastroenterol. 2019;54(9):1089–101. 2. Berry SK, Melmed GY. Quality indicators in inflammatory bowel disease. Intest Res. 2018;16(1):43–7.


2014 ◽  
Vol 28 (5) ◽  
pp. 275-285 ◽  
Author(s):  
Geoffrey C Nguyen ◽  
Shane M Devlin ◽  
Waqqas Afif ◽  
Brian Bressler ◽  
Steven E Gruchy ◽  
...  

BACKGROUND: There is a paucity of published data regarding the quality of care of inflammatory bowel disease (IBD) in Canada. Clinical quality indicators are quantitative end points used to guide, monitor and improve the quality of patient care. In Canada, where universal health care can vary significantly among provinces, quality indicators can be used to identify potential gaps in the delivery of IBD care and standardize the approach to interprovincial management.METHODS: The Emerging Practice in IBD Collaborative (EPIC) group generated a shortlist of IBD quality indicators based on a comprehensive literature review. An iterative voting process was used to select quality indicators to take forward. In a face-to-face meeting with the EPIC group, available evidence to support each quality indicator was presented by the EPIC member aligned to it, followed by group discussion to agree on the wording of the statements. The selected quality indicators were then ratified in a final vote by all EPIC members.RESULTS: Eleven quality indicators for the management of IBD within the single-payer health care system of Canada were developed. These focus on accurate diagnosis, appropriate and timely management, disease monitoring, and prevention or treatment of complications of IBD or its therapy.CONCLUSIONS: These quality indicators are measurable, reflective of the evidence base and expert opinion, and define a standard of care that is at least a minimum that should be expected for IBD management in Canada. The next steps for the EPIC group involve conducting research to assess current practice across Canada as it pertains to these quality indicators and to measure the impact of each of these indicators on patient outcomes.


Sign in / Sign up

Export Citation Format

Share Document